Haemonetics Corporation (NYSE: HAE) — Form 10-K Summary
Reporting period: Fiscal year ended March 30, 2024 (52 weeks), compared with fiscal 2023 ended April 1, 2023. This is an annual filing, not a stand-alone fourth-quarter report. Amounts are U.S. dollars.
Business context and financial performance
Haemonetics supplies medical technology for plasma and blood collection, interventional procedures, blood management and hospital transfusion services. It reports Plasma, Blood Center and Hospital segments. Management identifies Plasma and Hospital as growth businesses; Blood Center faces challenging markets and is being managed through cost reduction, product-line rationalization and review of unfavorable contracts.
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Net revenue | $1,309.1 million | $1,168.7 million | +12.0%; +12.7% constant currency |
| Gross profit / margin | $691.5 million / 52.8% | $615.1 million / 52.6% | Profit +12.4%; margin +0.2 points |
| Operating income / margin | $164.9 million / 12.6% | $156.0 million / 13.4% | Income +5.7%; margin -0.8 points |
| Net income / margin | $117.6 million / 9.0% | $115.4 million / 9.9% | Income +1.9%; margin -0.9 points |
| Diluted EPS | $2.29 | $2.24 | +2.2% |
| Operating cash flow | $181.8 million | $273.1 million | -$91.3 million |
| Capital expenditures | $66.3 million | $110.2 million | -$43.9 million |
Revenue by business unit was $565.9 million for Plasma (+13.9%), $276.1 million for Blood Center (-1.4%) and $445.4 million for Hospital (+19.8%). Plasma growth was driven primarily by volume and price. Hospital growth reflected vascular closure, hemostasis disposables and transfusion management. Blood Center was pressured by lower whole-blood disposable sales and foreign exchange, partly offset by apheresis disposables.
Management-reported segment operating income was $309.8 million for Plasma, $109.6 million for Blood Center and $184.2 million for Hospital. These are segment measures and do not equal consolidated operating income because corporate expenses and other adjustments are excluded.
Liquidity, cash flow and debt
- Cash and cash equivalents were $178.8 million at March 30, 2024, down from $284.5 million a year earlier. Working capital was $468.5 million (prior year $517.9 million); current ratio was 2.6 (prior year 3.1).
- Operating cash flow declined mainly because of replenishment of NexSys PCS devices. Investing cash outflow was $322.4 million, including $243.9 million for OpSens, net of cash acquired. Financing cash inflow was $38.2 million, mainly reflecting revolving-credit borrowings.
- Reported debt at year-end was approximately $807.8 million, including $494.8 million net carrying value of 0% convertible notes due 2026, $262.0 million net term-loan balance and $50.0 million revolver borrowings. The filing reports net debt of $629.0 million, calculated as cash less total debt.
- In April 2024, the company refinanced its credit facilities with a $250 million term loan and $750 million revolver, maturing in April 2029. At April 30, $230 million was drawn on the revolver. Separately, the $500 million convertible notes remain due March 2026.
- Management says available cash, operating cash flow and the revolving facility are expected to fund requirements for at least the next 12 months and known long-term needs. The company was in covenant compliance at March 30 and reported forecast compliance through March 29, 2025 under the then-applicable facilities.
Material changes and unusual items
- OpSens was acquired in December 2023 for approximately $254.5 million, or $243.9 million net of acquired cash. Preliminary purchase accounting included $172 million of identifiable intangibles and $99.4 million of goodwill. The auditor identified valuation of acquired intangibles as a critical audit matter.
- Attune Medical was acquired on April 1, 2024, after year-end, for $160 million upfront plus contingent consideration tied to sales growth and other milestones. The purchase was funded with cash and revolving borrowings.
- Fiscal 2024 included $10.4 million of intangible-asset impairment related to enicor GmbH, $13.9 million of portfolio-rationalization charges, $9.5 million of additional restructuring-related costs, and $11.2 million of OpSens integration and transaction costs. Operating income also reflected digital-transformation spending and amortization of OpSens inventory fair-value step-up.
- The company announced the end of life of the ClotPro analyzer and certain Blood Center products, primarily Whole Blood, with related manufacturing and facility actions. The Operational Excellence Program is expected to incur total charges of $85–$95 million by the end of FY2025; cumulative charges were $77 million at year-end.
- In August 2023, Haemonetics voluntarily recalled certain Whole Blood products. Cumulative charges for inventory, returns and customer claims were $6.8 million at year-end; further charges remain possible.
- The effective tax rate rose to 22.6% from 18.4%, primarily because a valuation-allowance release in FY2023 did not recur, partly offset by FY2024 tax benefits from foreign tax-law changes and stock compensation.
Outlook, management commentary and risks
The filing does not provide a clear numeric revenue, earnings or cash-flow forecast for FY2025. Management describes growth opportunities in Plasma and Hospital, while expecting Blood Center to be flat to decline at a low-single-digit rate. It cites demand for plasma-derived therapies and hospital adoption of interventional and advanced hemostasis technologies as opportunities, alongside continued pressure on blood collection markets.
- Customer concentration: The ten largest customers represented approximately 48% of revenue; CSL alone represented about 13%. CSL’s non-exclusive agreement runs through December 2025 and includes an approximately $85 million minimum purchase commitment for FY2025. Customer purchasing, renewal and pricing remain important risks.
- Competition and demand: Blood Center faces declining transfusion rates, lower whole-blood demand and price competition. Hospital products also face cost-containment and purchasing-approval pressures; Plasma depends on a small number of large customers.
- Execution and supply: Risks include integration of acquisitions, restructuring savings, ERP implementation through FY2025, supply-chain volatility, sole-source suppliers, sterilization capacity and inflation in plastics and other inputs.
- Regulation, product quality and litigation: Medical-device approvals and EU MDR/IVDR compliance may require time and expense. The filing describes the Whole Blood recall, an $8.7 million accrual for a proposed Illinois biometric-privacy class settlement, and patent litigation brought by Philips and IP2IPO concerning OpSens technologies. The relators’ qui tam claims were dismissed with prejudice, but the government’s claims were dismissed without prejudice.
- Other exposures: Variable-rate borrowing, foreign-exchange movements, convertible-note conversion or repayment obligations, cybersecurity and privacy incidents, geopolitical conditions and tax-law changes could affect results or liquidity. Management reported no known cybersecurity threats that had materially affected or were reasonably likely to materially affect the company.
The financial statements received an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective as of March 30, 2024. OpSens was excluded from the internal-control assessment under the acquired-business transition allowance.
Important facts for investors to verify
- Whether Plasma growth and CSL’s FY2025 minimum purchases support the outlook, and the implications of the contract’s December 2025 expiration.
- Post-acquisition debt, interest expense, covenant headroom and cash generation after the Attune Medical purchase and April 2024 refinancing.
- Hospital growth and integration progress for OpSens and Attune Medical, including realization of expected commercial benefits and the finalization of OpSens purchase accounting.
- Additional costs or customer effects from the Whole Blood recall, portfolio rationalization, restructuring and ERP implementation.
- Developments in the Philips/OpSens patent case and completion of the biometric-privacy settlement administration.
- Whether operating cash flow recovers from FY2024’s decline and whether margin pressure from expenses, taxes and acquisition-related costs moderates.